Akèy › Kansè pwostat › Tennessee › Nashville
Etid klinik pou Kansè pwostat nan Nashville, TN
43 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Ap rekriteFaz 1/2
- GSK Investigational Site, Nashville
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Ap rekriteFaz 3
- Urology Associates, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Ap rekriteFaz 1
- Tennessee Oncology, Nashville
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Nashville
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
- Urology Associates, Nashville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Ap rekriteFaz 3
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic, Nashville
- Tennessee Oncology, PLLC - Nashville Saint Thomas West, Nashville
- ak 7 plis
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Tennessee Oncology, Nashville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 3
- Sarah Cannon Research Institute Oncology Partners, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Ap rekriteFaz 3
- Research Site, Nashville
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Ap rekriteFaz 2
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ap rekriteFaz 3
- SCRI Oncology Partners ( Site 0074), Nashville
- Henry-Joyce Cancer Clinic ( Site 0042), Nashville
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 1
- Sarah Cannon Research Institute Oncology Partners, Nashville
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Ap rekriteFaz 3
- Urology Associates of Nashville, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Center, Nashville
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Ap rekriteFaz 2
- Tennessee Oncology Nashville, Nashville
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Ap rekriteFaz 3
- Research Site, Nashville
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Ap rekriteFaz 2
- Sarah Cannon Research Institute, Nashville
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- United States Oncology Regulatory Affairs Corporate Office, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ap rekriteFaz 2
- Henry-Joyce Cancer Clinic, Nashville
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Ap rekriteFaz 1
- Sarah Cannon Research, Nashville
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Ap rekriteFaz 1/2
- Tennessee Oncology PLLC, Nashville
PSMA PET Combined With MRI for the Detection of PCa
Ap rekriteFaz 3Volontè an sante akeyi
- Urology Associates of Nashville, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #102, Nashville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- Vanderbilt University/Ingram Cancer Center, Nashville
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Ap rekriteFaz 1
- Urology Associates PC, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Vanderbilt-Ingram Cancer Center, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Nashville
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ap rekriteFaz 3
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #6, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Ap rekriteFaz 1/2
- SCRI Oncology Partners, Nashville
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Seattle, WA42 etid
- Washington, DC38 etid
- Dallas, TX36 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
- Myelom Miltip32 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.